about
The clinical potential of blood-proteomics in multiple sclerosisMultiple sclerosis: modulation of toll-like receptor (TLR) expression by interferon-β includes upregulation of TLR7 in plasmacytoid dendritic cells.Expression of GM-CSF in T Cells Is Increased in Multiple Sclerosis and Suppressed by IFN-β Therapy.Cytokine-neuroantigen fusion proteins as a new class of tolerogenic, therapeutic vaccines for treatment of inflammatory demyelinating disease in rodent models of multiple sclerosisDifferential transcriptional profiles mediated by exposure to the cannabinoids cannabidiol and Δ9-tetrahydrocannabinol in BV-2 microglial cells.Interferon-β1b increases Th2 response in neuromyelitis optica.Use of a standardized MxA protein measurement-based assay for validation of assays for the assessment of neutralizing antibodies against interferon-β.CD80+ and CD86+ B cells as biomarkers and possible therapeutic targets in HTLV-1 associated myelopathy/tropical spastic paraparesis and multiple sclerosis.Adrenergic and dopaminergic modulation of immunity in multiple sclerosis: teaching old drugs new tricks?Subcutaneous IFN-β1a to treat relapsing-remitting multiple sclerosis.Influence of type-I Interferon receptor expression level on the response to type-I Interferons in human pancreatic cancer cells.The hematopoietic regulator, ELF-1, enhances the transcriptional response to Interferon-β of the OAS1 anti-viral gene.B-cell targeting agents in the treatment of multiple sclerosis.IFN-β Facilitates Neuroantigen-Dependent Induction of CD25+ FOXP3+ Regulatory T Cells That Suppress Experimental Autoimmune Encephalomyelitis.Cell based assay identifies TLR2 and TLR4 stimulating impurities in Interferon betaBAb and MxA as functional biomarkers in routine clinical laboratories for the determination of anti-IFN-beta antibodies and their bioactivity levels in multiple sclerosis patients.Metallic gold beads in hyaluronic acid: a novel form of gold-based immunosuppression? Investigations of the immunosuppressive effects of metallic gold on cultured J774 macrophages and on neuronal gene expression in experimental autoimmune encephalomComparative pharmacogenetics of multiple sclerosis: IFN-β versus glatiramer acetate.miR-145 and miR20a-5p Potentially Mediate Pleiotropic Effects of Interferon-Beta Through Mitogen-Activated Protein Kinase Signaling Pathway in Multiple Sclerosis Patients.
P2860
Q34732881-EE6377D1-5579-41ED-A966-AD272A6E8F05Q34947419-BD025066-392F-42BA-A638-513F8411136AQ35613048-0DECDAFC-2867-46E8-91AC-FD8A97D14138Q36174813-986AF4F9-BCF4-4E3E-9595-3BE7766A2576Q36176444-3E525FB1-AB4F-440F-883F-C4D5E5A25E1DQ36396409-D9F3D0E0-76A8-4A28-A42D-8BC5E0AFB177Q37272709-5223F0B3-DAC2-412A-991D-9C204810F716Q37579811-44C63538-E509-4E86-A61D-F1D1B04D16CDQ38052870-4FBE963C-DF6B-4EFE-A54B-0A59CEA73DC1Q38058831-383613F8-24D6-4523-9291-6DFD4587CA0FQ38281748-33C2E52B-50F3-471F-BA25-418895E17D2CQ38813940-9FFBA07E-E5FF-47A2-8C32-CEFA03388A75Q39431517-1A9377EF-D023-4923-8C8A-3BA9F29D0B0EQ40543124-171A3AD6-859E-43A4-8382-E0740AFAD1E8Q41620233-5F8568B5-79FC-40CF-ABFB-7F5BE5DC978CQ43637145-7F6BC81D-2276-4186-9261-C0514889F423Q51011789-12AE2296-95A1-49E8-86E9-64324C66317BQ51089837-AC83E658-CE4B-4439-ACD2-3DA630E77571Q51381933-D9463411-6B1B-41C8-8793-6D10CD33B098
P2860
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Beta-interferon for multiple sclerosis.
@ast
Beta-interferon for multiple sclerosis.
@en
type
label
Beta-interferon for multiple sclerosis.
@ast
Beta-interferon for multiple sclerosis.
@en
prefLabel
Beta-interferon for multiple sclerosis.
@ast
Beta-interferon for multiple sclerosis.
@en
P1476
Beta-interferon for multiple sclerosis.
@en
P2093
Richard A Rudick
Susan E Goelz
P304
P356
10.1016/J.YEXCR.2011.03.002
P407
P577
2011-03-21T00:00:00Z